key: cord-0718857-gcp04jh9 authors: Grinspan, Zachary M.; Mytinger, John R.; Baumer, Fiona M.; Ciliberto, Michael A.; Cohen, Bruce H.; Dlugos, Dennis J.; Harini, Chellamani; Hussain, Shaun A.; Joshi, Sucheta M.; Keator, Cynthia G.; Knupp, Kelly G.; McGoldrick, Patricia E.; Nickels, Katherine C.; Park, Jun T.; Pasupuleti, Archana; Patel, Anup D.; Shahid, Asim M.; Shellhaas, Renee A.; Shrey, Daniel W.; Singh, Rani K.; Wolf, Steven M.; Yozawitz, Elissa G.; Yuskaitis, Christopher J.; Waugh, Jeff L.; Pearl, Phillip L. title: Management of Infantile Spasms During the COVID-19 Pandemic date: 2020-06-23 journal: J Child Neurol DOI: 10.1177/0883073820933739 sha: c3617397f3cd9c53842c450708619409dd2e7839 doc_id: 718857 cord_uid: gcp04jh9 Circumstances of the COVID-19 pandemic have mandated a change to standard management of infantile spasms. On April 6, 2020, the Child Neurology Society issued an online statement of immediate recommendations to streamline diagnosis and treatment of infantile spasms with utilization of telemedicine, outpatient studies, and selection of first-line oral therapies as initial treatment. The rationale for the recommendations and specific guidance including follow-up assessment are provided in this manuscript. These recommendations are indicated as enduring if intended to outlast the pandemic, and limited if intended only for the pandemic health care crisis but may be applicable to future disruptions of health care delivery. Infantile spasms are an early-life epilepsy syndrome and epileptic encephalopathy characterized by epileptic spasms that typically occur in clusters. The incidence is 1 per 2400 to 5500 live births, [1] [2] [3] [4] [5] [6] [7] roughly similar to the incidence of cystic fibrosis, 8 tetralogy of Fallot, 9 and type 1 diabetes. 10 The age of onset is usually between 2 and 9 months, though infantile spasms can present up to age 2 years. 11 Rapid diagnosis and treatment of infantile spasms is a key priority for pediatric neurologists because timely delivery of effective treatment improves the likelihood of resolution of epileptic spasms and improves cognitive outcomes. [12] [13] [14] [15] Developmental outcomes at 18 months depend strongly on pre-existing risk of developmental impairment, pre-existing epilepsy at the time of diagnosis, etiology, and treatment response. 14, 15 For example, in infants with a history of hypoxic ischemic encephalopathy, infantile spasms is a marker of injury severity and associated with significant neurodevelopmental disability. [16] [17] [18] In contrast, in infants with normal brain magnetic resonance imaging (MRI), normal prior development, no prior epilepsy, no clear etiology, and brisk response to treatment (within 7 days), a normal neurodevelopmental trajectory is common. 12, 14, 19 In the United States, the initial evaluation for infantile spasms typically includes an inpatient admission for video electroencephalography (EEG). 20 The hospital admission allows the clinical team to confirm the diagnosis, begin treatment, investigate the etiology (ie, via brain MRI and other testing), and provide counseling to the family. When adrenocorticotropin (ACTH) is prescribed, the inpatient admission also allows the clinical team to coordinate training for caregivers on how to administer injections, obtain health insurance authorization, and arrange home delivery. When hormonal treatments are prescribed (ACTH or oral corticosteroids), infants are often monitored during therapy for hypertension and glucosuria. Modern regimens are typically brief (2 weeks at a high dose followed by a 2-week taper) because prolonged courses of ACTH or prednisolone risk immunosuppression and severe hypertension. 21 The COVID-19 pandemic has strained traditional health care delivery. At the time of writing (April 2020), COVID-19 infections are common among patients admitted to hospitals, and many pediatric wards are occupied by sick adults. Local, regional, and national governments worldwide have instituted social distancing measures to reduce community transmission, including closing businesses and public spaces, and ordering the general public to stay at home. Every visit to a health system puts children and their families at risk for infection, and increases the risk of inadvertent exposure to health care providers. The risk of exposure is magnified due to transmission by presymptomatic infected COVID-19 carriers 22 and airborne (ie, aerosol) transmission of COVID-19. 23, 24 Although COVID-19 infections are milder in pediatric populations, infants and immunocompromised individuals have the most severe disease among infected children. 25, 26 In recognition of the need to balance rapid evaluation of infantile spasms with the public health demands of a pandemic, a group of pediatric epilepsy experts in the United States drafted recommendations for the diagnosis and treatment of infantile spasms in the COVID-19 era. The recommendations are endorsed by the Child Neurology Society, the North American-based professional organization of child neurologists established in 1972. 27 The text was drafted in collaboration with the Pediatric Epilepsy Research Consortium, a group of 54 US academic pediatric epilepsy centers committed to collaborative, collegial, practice changing research. 28 The authors drafted, edited, and finalized an initial statement via e-mail, telephone, and teleconference during the week of March 30 to April 6, 2020. These were published online through the Child Neurology Society website on April 6, 2020. 29 This manuscript reproduces the recommendations, with minor modifications, supplemented with references and rationale. We have also indicated if each recommendation is limited (ie, intended only for the COVID-19 pandemic health care crisis) or enduring (ie, intended to outlast the pandemic). The recommendations are targeted to the current pandemic but may be applicable to future disruptions of health care delivery. The initial clinical visit for suspected infantile spasms may be performed by telemedicine or video conference. [Enduring] In-person access to child neurology clinical expertise is uneven in the United States. 30, 31 Telemedicine allows clinicians to evaluate children from afar. Prior to the COVID-19 pandemic, growing experience suggested telemedicine was a feasible and effective way to expand access to neurology care for children. [32] [33] [34] [35] [36] For infantile spasms, clinical decision-making relies on the infant's medical and neurologic history and the characteristics of the events -these can be evaluated remotely. Instruct parents to obtain and share video recordings of several consecutive typical events. Review the videos prior to or during the initial clinical encounter. [Enduring] Given that 92% of US adults aged 30-49 years own a smartphone, 37 it is reasonable to ask a parent or caregiver to obtain home video recording of the events. Individual epileptic spasms are typically flexor movements (though they can be extensor) of the arms, legs, and/or neck, usually lasting less than 2 seconds. 38 The movement lasts longer than myoclonus, but briefer than a tonic seizure. Of key importance to the diagnosis of infantile spasms, the epileptic spasms usually occur at regular intervals (every 3-30 seconds) 39 within clusters lasting several minutes. Parents and caregivers should be requested to capture at least 3 events, including the interval between events (intervals less than 3 seconds are essentially never epileptic spasms). The entire body and face should be within camera view along with adequate lighting. If possible, the recordings should include the infant in multiple positions (eg supine and seated) and multiple states (eg awake and asleep). Ask about light spots on the skin and/or perform skin examination (ie, as a possible indicator of tuberous sclerosis complex.) [Enduring] Tuberous sclerosis complex is a common cause of infantile spasms. 40, 41 Two in five infants with tuberous sclerosis complex will develop infantile spasms, 42 and in some cases, infantile spasms are the presenting symptom. 43 Hypomelanotic macules are present in 90% of patients with tuberous sclerosis complex and are typically present at birth or during infancy. 44 Subtle findings may be missed via telemedicine; thus, a full dermatologic examination with Wood's lamp should be performed when possible. Of important note, tuberous sclerosis complex is a clinical diagnosis based on examination and imaging and does not require genetic confirmation. 44 EEG confirmation is strongly encouraged and should include at least 1 sleep-wake cycle. [Enduring] There are many mimics of infantile spasms, including gastroesophageal reflux, benign shuddering attacks, benign myoclonus of infancy, and other seizure types (eg, myoclonic or tonic seizures). 45 Therefore, EEG is foundational to establish the diagnosis of infantile spasms. EEG typically shows epileptiform abnormalities potentiated by sleep. 46 Of important note, hypsarrhythmia is not required for diagnosis. Hypsarrhythmia is absent in as many as one-quarter of cases, 7, 47, 48 and its presence at diagnosis does not predict treatment response. 47 If the EEG background is normal but clinical concern is high, then a longer video recording that captures the events should be obtained. During the COVID-19 pandemic, outpatient EEG is preferred over inpatient admission. [Limited] Inpatient care allows rapid coordination of video EEG, brain MRI, laboratory testing, treatment initiation (or coordination), and caregiver education, as well as access to first-line medications like ACTH and vigabatrin, which are not available in commercial outpatient pharmacies. However, the need for inpatient care is not driven by a meaningful risk of cardiorespiratory instability or acute neurologic decompensation. Thus, the benefits of inpatient care coordination must be balanced with the risk of exposure to infected individuals, such as health care workers or other admitted patients and their families. After diagnosis, if the etiology is uncertain, obtain a brain MRI (urgent; within 1-3 days) and perform genetic testing (expedited). [Enduring] If the etiology of infantile spasms is not clear after thorough history and physical examination, a brain MRI is crucial to the etiological workup, as it can affect treatment choices. Two examples follow. First, the diagnosis of tuberous sclerosis complex may be made by brain MRI, because skin lesions can be subtle, and affected children may first come to medical attention because of infantile spasms. 43 The diagnosis affects treatment selection, as tuberous sclerosis complex is preferentially treated with vigabatrin (rather than hormonal therapy). 49, 50 Second, when a structural brain lesion is identified, an epilepsy surgery evaluation can be expedited if standard medical treatment fails. 51, 52 Genetic testing is also a high-yield priority early in the diagnostic workup. A pathogenic genetic abnormality is found in nearly half of those tested, 11 including in 24% of those where the initial history, examination, and MRI do not identify a cause. 53 A comprehensive epilepsy gene panel is generally recommended as the first-line test at this time, and microarray may be considered in the presence of dysmorphism or other organ system involvement. Select from among ACTH (adrenocorticotropic hormone), high-dose prednisolone (4-8 mg/kg/d), and vigabatrin, unless there are contraindications to all three. [Enduring] ACTH, prednisolone, and vigabatrin have the strongest evidence to support use as the first line for infantile spasms. This recommendation is backed by consensus statements, structured literature reviews, guidelines from national organizations, and quality measures, based on a synthesis of evidence that includes high-quality randomized controlled trials. [54] [55] [56] [57] During the COVID-19 pandemic, initiation of high-dose oral prednisolone in the outpatient setting is the preferred initial treatment for infantile spasms for etiologies other than tuberous sclerosis complex. [Limited] Among the three recommended first-line therapies for infantile spasms, prednisolone has several advantages that make it preferable during the COVID-19 pandemic. It is inexpensive, readily available in commercial pharmacies, and orally administered. This is in contrast with ACTH and vigabatrin, which require special training of caregivers (ACTH, injections; vigabatrin, mixing of sachets), use of subspecialty pharmacies, and preapproval by insurance. High-dose prednisolone regimens (4-8 mg/kg/d) have better response rates than low dose prednisolone, 58 though the optimal regimen has not been established. We provide two sample regimens, one used in European clinical trials 14, 59 and one used by many US programs 60,61 ( Table 1) . Three additional comments deserve mention. First, if evaluating infantile spasms in the inpatient setting, length of stay may be reduced (and COVID-19 risk minimized) by selection of prednisolone or vigabatrin over ACTH. 62 Second, this limited recommendation is intended to help clinicians balance the risks of COVID-19 exposure with the provision of timely clinical care, and should not be used to justify denial of insurance coverage or payment for inpatient hospitalization, for use of ACTH, or for use of vigabatrin. Third, some clinicians may elect to start prednisolone and then switch to ACTH or vigabatrin when available (and provide outpatient or home training), or add vigabatrin based on potential benefits of combination therapy. 14, 63 For tuberous sclerosis complex, vigabatrin is preferred if immediately available. If access is delayed, while waiting for vigabatrin, initiate oral prednisolone and obtain an echocardiogram. [Enduring] Infantile spasms due to tuberous sclerosis complex respond particularly well to vigabatrin. [54] [55] [56] However, access to medications from specialty pharmacies may be delayed during the COVID-19 pandemic, and early treatment of infantile spasms is essential. Prednisolone is widely available and can be easily started while waiting to obtain vigabatrin. ACTH has been reported to increase the size of cardiac rhabdomyomas 64, 65 ; thus, use of hormonal therapy in tuberous sclerosis complex should include echocardiography evaluation. Avoid non-standard therapy as the first treatment choice for infantile spasms (ie, avoid topiramate, ketogenic diet, etc.). [Enduring] Other anti-seizure medications and dietary therapies are not as efficacious as hormonal therapy or vigabatrin and should not be administered as initial therapy. In particular, though topiramate showed early promise, 66, 67 follow-up analyses have failed to show efficacy against infantile spasms. [68] [69] [70] [71] [72] Zonisamide 73, 74 and levetiracetam 69 also lack compelling evidence of efficacy. Ketogenic diet 75, 76 and valproic acid 50 may have efficacy, but the evidence does not support their use as initial treatment for infantile spasms. For infants treated with prednisolone or ACTH, consider GI prophylaxis with a proton pump inhibitor or H2 blocker. [Enduring] Medications for prophylactic gastric acid suppression during the treatment of infantile spasms is common practice, 49 and their overall efficacy in children is well established. Three commonly used and readily available regimens i include: The authors have cared for children for whom high-dose hormonal therapy was initiated, but there was no follow-up at 2 weeks to initiate the taper. Therefore, the taper should be specified from the onset of treatment to prevent medication over-exposure or abrupt cessation. Follow infants closely via telehealth, video conference, or phone calls, at least weekly. If using hormonal therapy, measure blood pressure at least weekly during treatment. Laboratory testing should be used sparingly, unless there are clinical indications that suggest a specific need for more than routine monitoring. [Limited] Clinically important laboratory abnormalities are often accompanied by clinical signs (ie, lethargy or reduced feeding), but hypertension may be initially asymptomatic. Hormonal therapy of infantile spasms commonly leads to hypertension and, in some cases, cardiomegaly. 59, 77 When hypertension occurs, it typically begins within a week of therapy, though there may be a delayed response after 3 weeks. 21, 77 Hypertension typically resolves after medication discontinuation. 77 In older series, treatment-related deaths occurred as a result of infection and hemorrhage. 21 Clinical resolution of epileptic spasms per caregiver report can be misleading, as spasms can become less obvious as a partial response to treatment. 79 Caregivers may underestimate the number of spasms or miss subtle or single isolated spasms. 54 In addition, EEG abnormalities may persist and are typically most obvious during sleep. 46 Caregiver-reported clinical resolution can be confirmed by an EEG (ideally with video) that captures at least one sleep-wake cycle, and shows neither epileptic spasms nor hypsarrhythmia. ZMG, JRM PLP and wrote the initial and final drafts of the manuscript. All authors contributed to the literature review, data analysis, and careful review and editing of the text. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The authors received no financial support for the research, authorship, and/or publication of this article. Note i. Ranitidine was often prescribed in the recent past; it is not currently available because of concerns about a contaminant that may increase cancer risk (https://www.fda.gov/news-events/ press-announcements/fda-requests-removal-all-ranitidine-prod ucts-zantac-market). Occurrence and outcome of epilepsy in children younger than 2 years Incidence and outcome of epilepsy syndromes with onset in the first year of life: a retrospective population-based study Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: a population-based study The descriptive epidemiology of infantile spasms among Atlanta children. Epilepsia Epidemiology of infantile spasms in Sweden Epidemiologic features of infantile spasms in Iceland Cystic fibrosis Tetralogy of Fallot Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study Why west? Comparisons of clinical, genetic and molecular features of infants with and without spasms Infantile spasms: outcome in clinical studies Epileptic encephalopathies Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study MRI findings in infants with infantile spasms after neonatal hypoxic-ischemic encephalopathy Impact of therapeutic hypothermia on infantile spasms: an observational cohort study Prediction of future epilepsy in neonates with hypoxic-ischemic encephalopathy who received selective head cooling Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone Treatment of infantile spasms ACTH therapy in infantile spasms: side effects Temporal dynamics in viral shedding and transmissibility of COVID-19 Airborne transmission of severe acute respiratory syndrome coronavirus-2 to healthcare workers: a narrative review Airborne or droplet precautions for health workers treating COVID-19 Epidemiology of COVID-19 among children in China CDC Covid-19 Response Team. Coronavirus Disease 2019 in Children-United States Formation and growth of the Child Neurology Society Meaningful results in a jiffy-a PERC of multicenter collaborations Management of Infantile Spasms During the COVID-19 Pandemic Supply and demand analysis of the current and future US neurology workforce Report of the AAP/CNS Joint Taskforce Hospital utilization among rural children served by pediatric neurology telemedicine clinics Pediatric teleneurology: a model of epilepsy care for rural populations Telemedicine in pediatric neurology A comparison of epilepsy patients in a traditional ambulatory clinic and a telemedicine clinic. Epilepsia Mobile Fact Sheet Precise characterization and quantification of infantile spasms Clinical spectrum of epileptic spasms in children Response to treatment in a prospective national infantile spasms cohort West syndrome: etiological and prognostic aspects The natural history of epilepsy in tuberous sclerosis complex Presentation and diagnosis of tuberous sclerosis complex in infants International Tuberous Sclerosis Complex Consensus G. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference The spectrum of benign myoclonus of early infancy: clinical and neurophysiologic features in 102 patients Reappraisal of interictal electroencephalograms in infantile spasms The impact of hypsarrhythmia on infantile spasms treatment response: observational cohort study from the National Infantile Spasms Consortium A retrospective study on aetiology based outcome of infantile spasms Pediatric Epilepsy Research Consortium SoIS. The current evaluation and treatment of infantile spasms among members of the Child Neurology Society Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Infantile spasms: who are the ideal surgical candidates? Hemispherotomy for isolated infantile spasms following perinatal ischemic stroke How should children with West syndrome be efficiently and accurately investigated? Results from the National Infantile Spasms Consortium. Epilepsia Infantile spasms: a U Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics Quality improvement in neurology: child neurology quality measure set: Executive summary Prednisolone/prednisone as adrenocorticotropic hormone alternative for infantile spasms: a meta-analysis of randomized controlled trials The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial Treatment of infantile spasms with very high dose prednisolone before high dose adrenocorticotropic hormone Very-high-dose prednisolone before ACTH for treatment of infantile spasms: evaluation of a standardized protocol Compliance with standard therapies and remission rates after implementation of an infantile spasms management guideline Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial Images in cardiology. Enlargement of cardiac rhabdomyoma and myocardial ischaemia during corticotropin treatment for infantile spasm Rapid enlargement of cardiac rhabdomyoma during corticotropin therapy for infantile spasms Topiramate for the treatment of infantile spasms A pilot study of topiramate in the treatment of infantile spasms Infantile spasms respond poorly to topiramate Ineffectiveness of topiramate and levetiracetam in infantile spasms non-responsive to steroids. Open labeled randomized prospective study Outcomes among patients with infantile spasms treated with hormonal therapy and adjuvant topiramate versus hormonal therapy alone Topiramate as an adjunct in the management of west syndrome High-dose prednisone therapy for infantile spasms and late-onset epileptic spasms in China: the addition of topiramate provides no benefit Limited efficacy of zonisamide in the treatment of refractory infantile spasms Safety, tolerability, and effectiveness of oral zonisamide therapy in comparison with intramuscular adrenocorticotropic hormone therapy in infants with West syndrome Infantile spasms treated with the ketogenic diet: prospective single-center experience in 104 consecutive infants Efficacy of ketogenic diet for infantile spasms: a systematic review Cardiac size and function during adrenocorticotropic hormone-induced systolic systemic hypertension in infants The response to ACTH is determined early in the treatment of infantile spasms Infantile spasms: diagnosis and assessment of treatment response by video-EEG